Translational repression of p53 by RNPC1,a p53 target over expressed in lymphomas

Genes and Development

Volumn 25, Issue 14, 2011, Pages 1528-1543

  Zhang, Jin ^a   Cho, Seong Jun ^a   Shu, Limin ^a   Yan, Wensheng ^a   Guerrero, Teri ^a   Kent, Michael ^a   Skorupski, Katherine ^a   Chen, Hongwu ^a   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

eIF4E; P53; RBM38; RNA binding protein; RNPC1; Translational control

Indexed keywords

INITIATION FACTOR 4E; PROTEIN P53; RNA BINDING PROTEIN; RNPC1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; DOG; GENE OVEREXPRESSION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSLATION REGULATION;

5' UNTRANSLATED REGIONS; ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; DOGS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; LYMPHOMA; MICE; MICE, KNOCKOUT; POLY U; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER; RNA-BINDING PROTEINS; STRESS, PHYSIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

CANIS FAMILIARIS;

EID: 79960424486     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.2069311     Document Type: Article

References (61)

1. Barak Y, Juven T, Haffner R, Oren M. 1993. mdm2 expressionis induced by wild type p53 activity. EMBO J 12: 461-468.
2. Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z, Orr-Urtreger A. 2002. Multiple genes inhuman 20q13 chromosomal region are involved in anadvanced prostate cancer xenograft. Cancer Res 62: 6803-6807.
3. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. 2006. TIGAR, a p 53-inducibleregulator of glycolysis and apoptosis. Cell 126: 107-120.
4. Blobel G, Sabatini D. 1971. Dissociation of mammalian polyribosomesinto subunits by puromycin. Proc Natl Acad Sci68: 390-394.
5. Bonifacino JS. 2001. Metabolic labeling with amino acids. CurrProtoc Protein Sci 7. 1. 1-7.1. 10. doi: 10.1002/0471143030.cb0701s00.
6. Brosh R, Rotter V. 2009. When mutants gain new powers: newsfrom the mutant p53 field. Nat Rev Cancer 9: 701-713.
7. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van deWiel MA, van Criekinge W, Thas O, Matthai A, Cuesta MA, et al. 2009. Multiple putative oncogenes at the chromosome20q amplicon contribute to colorectal adenoma to carcinomaprogression. Gut 58: 79-89.
8. Chen J, Kastan MB. 2010. 59-39-UTR interactions regulatep53 mRNA translation and provide a target for modulatingp53 induction after DNA damage. Genes Dev 24: 2146-2156.
9. Cho SJ, Zhang J, Chen X. 2010. RNPC1 modulates the RNAbinding activity of, and cooperates with, HuR to regulate p21mRNA stability. Nucleic Acids Res 38: 2256-2267.
10. Constantinou C, Clemens MJ. 2007. Regulation of translationfactors eIF4GI and 4E-BP1 during recovery of protein synthesisfrom inhibition by p53. Cell Death Differ 14: 576-585.
11. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993.WAF1, a potential mediator of p53 tumor suppression. Cell75: 817-825.
12. Fu L, Benchimol S. 1997. Participation of the human p53 39UTRin translational repression and activation following g-irradiation. EMBO J 16: 4117-4125.
13. Fu L, Ma W, Benchimol S. 1999. A translation repressor elementresides in the 39 untranslated region of human p53 mRNA. Oncogene 18: 6419-6424.
14. Galban S, Martindale JL, Mazan-Mamczarz K, Lopez de SilanesI, Fan J, Wang W, Decker J, Gorospe M. 2003. Influence of theRNA-binding protein HuR in pVHL-regulated p53 expressionin renal carcinoma cells. Mol Cell Biol 23: 7083-7095.
15. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. 1990.Anticardiolipin antibodies (ACA) directed not to cardiolipinbut to a plasma protein cofactor. Lancet 335: 1544-1547.
16. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, et al. 2006. Prognosis and gene expression profiling of20q13-amplified breast cancers. Clin Cancer Res 12: 4533-4544.
17. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AI, Lieberman PH. 1990.Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 66: 480-490.
18. Haghighat A, Mader S, Pause A, Sonenberg N. 1995. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 14: 5701-5709.
19. Harms KL, Chen X. 2007. Histone deacetylase 2 modulates p53transcriptional activities through regulation of p53-DNAbinding activity. Cancer Res 67: 3145-3152.
20. Harms K, Nozell S, Chen X. 2004. The common and distincttarget genes of the p53 family transcription factors. Cell Mol Life Sci 61: 822-842.
21. Helmbold H, Komm N, Deppert W, Bohn W. 2009. Rb2/p130 isthe dominating pocket protein in the p53-p21 DNA damageresponse pathway leading to senescence. Oncogene 28:3456-3467.
22. Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, Roemen G, Arends JW, Williams R, Giaretti W, et al. 2002. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology123: 1109-1119.
23. Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, Hensold JO. 2002. p53 activation results in rapid dephosphorylationof the eIF4E-binding protein 4E-BP1, inhibitionof ribosomal protein S6 kinase and inhibition of translationinitiation. Oncogene 21: 5325-5334.
24. Knosel T, Schluns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I. 2003. Genetic imbalances with impact on survivalin colorectal cancer patients. Histopathology 43: 323-331.
25. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM. 1999. Chromosome arm 20q gainsand other genomic alterations in colorectal cancer metastaticto liver, as analyzed by comparative genomic hybridizationand fluorescence in situ hybridization. Genes Chromosomes Cancer 25: 82-90.
26. Kortlever RM, Higgins PJ, Bernards R. 2006. Plasminogen activator inhibitor-1 is a critical downstream target of p53in the induction of replicative senescence. Nat Cell Biol 8:877-884.
27. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG. 2002. Identification of tumor associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100: 2123-2131.
28. Kruse JP, GuW. 2009.Modes of p53 regulation. Cell 137: 609-622.
29. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, et al. 2006. Frequency, prognostic impact, and subtypeassociation of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13amplifications in breast cancers. BMC Cancer 6: 245. doi:10.1186/1471-2407-6-245.
30. MacVean DW, Monlux AW, Anderson PS Jr, Silberg SL, Roszel JF. 1978. Frequency of canine and feline tumors in a definedpopulation. Vet Pathol 15: 700-715.
31. Maltzman W, Czyzyk L. 1984. UV irradiation stimulates levelsof p53 cellular tumor antigen in non transformed mouse cells. Mol Cell Biol 4: 1689-1694.
32. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. 1994.Post-thymic T cell lymphomas frequently over express p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144: 573-584.
33. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, Gorospe M. 2003. RNA-bindingprotein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci 100: 8354-8359.
34. Miyamoto S, Hidaka K, Jin D, Morisaki T. 2009. RNA-bindingproteins Rbm38 and Rbm24 regulate myogenic differentiationvia p21-dependent and -independent regulatory pathways. Genes Cells 14: 1241-1252.
35. Newcomb EW. 1995. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 17: 211-221.
36. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB, Oren M. 2008. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell32: 180-189.
37. Oka T, Sarker AB, Teramoto N, Yoshino T, Akagi T. 1998.p53 protein expression in non-Hodgkin's lymphomas isinfrequently related to p53 gene mutations. Pathol Int 48:15-21.
38. Paoloni M, Khanna C. 2008. Translation of new cancer treatmentsfrom pet dogs to humans. Nat Rev Cancer 8: 147-156.
39. Peritz T, Zeng F, Kannanayakal TJ, Kilk K, Eiriksdottir E, Langel U, Eberwine J. 2006. Immunop recipitation of mRNA-proteincomplexes. Nat Protoc 1: 577-580.
40. Qian Y, Zhang J, Yan B, Chen X. 2008. DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53family, mediates p53-dependent premature senescence. J BiolChem 283: 2896-2905.
41. Ray PS, Grover R, Das S. 2006. Two internal ribosome entrysites mediate the translation of p53 isoforms. EMBO Rep 7:404-410.
42. Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptionalcontrol of human p53-regulated genes. Nat Rev Mol Cell Biol9: 402-412.
43. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. 2000.p53 binding protein 1 (53BP1) is an early participant in thecellular response to DNA double-strand breaks. J Cell Biol 151: 1381-1390.
44. Schumacher B, Hanazawa M, Lee MH, Nayak S, Volkmann K, Hofmann ER, Hengartner M, Schedl T, Gartner A. 2005.Translational repression of C. elegans p53 by GLD-1regulates DNA damage-induced apoptosis. Cell 120: 357-368.
45. Scoumanne A, Chen X. 2006. The epithelial cell transforming sequence 2, a guanine nucleotide exchange factor for RhoGTPases, is repressed by p53 via protein methyl l transferases and is required for G1-S transition. Cancer Res 66: 6271-6279.
46. Scoumanne A, Cho SJ, Zhang J, Chen X. 2011. The cyclindependentkinase inhibitor p21 is regulated by RNA-bindingprotein PCBP4 via mRNA stability. Nucleic Acids Res 39:213-214.
47. Shu L, Yan W, Chen X. 2006. RNPC1, an RNA-binding proteinand a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. Genes Dev 20: 2961-2972.
48. Stebbins-Boaz B, Cao Q, de Moor CH, Mendez R, Richter JD.1999. Maskin is a CPEB-associated factor that transiently interacts with elF-4E. Mol Cell 4: 1017-1027.
49. Takagi M, Absalon MJ, McLure KG, Kastan MB. 2005. Regulationof p53 translation and induction after DNA damage byribosomal protein L26 and nucleolin. Cell 123: 49-63.
50. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ. 2000. Frequent amplification ofchromosomal region 20q12-q13 in ovarian cancer. ClinCancer Res 6: 1833-1839.
51. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408: 307-310.
52. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
53. Wilhelm JE, Hilton M, Amos Q, Henzel WJ. 2003. Cup is aneIF4E binding protein required for both the translational repression of oskar and the recruitment of Barentsz. J Cell Biol 163: 1197-1204.
54. Wu X, Bayle JH, Olson D, Levine AJ. 1993. The p53-mdm-2autoregulatory feedback loop. Genes Dev 7: 1126-1132.
55. Yang DQ, Halaby MJ, Zhang Y. 2006. The identification of aninternal ribosomal entry site in the 59-untranslated region ofp53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 25: 4613-4619.
56. Zhang J, Chen X. 2007. DNp73 modulates nerve growth factormediatedneuronal differentiation through repression of TrkA. Mol Cell Biol 27: 3868-3880.
57. Zhang J, Chen X. 2008. Posttranscriptional regulation of p53 andits targets by RNA-binding proteins. Curr Mol Med 8: 845-849.
58. Zhang J, Chen X, Kent MS, Rodriguez CO, Chen X. 2009.Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor. Mol Cancer Res 7: 67-78.
59. Zhang J, Cho SJ, Chen X. 2010. RNPC1, an RNA-binding proteinand a target of the p53 family, regulates p63 expressionthrough mRNA stability. Proc Natl Acad Sci 107: 9614-9619.
60. Zheng SL, Xu J, Isaacs SD, Wiley K, Chang B, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. 2001. Evidence for a prostate cancer linkage to chromosome 20 in 159hereditary prostate cancer families. Hum Genet 108: 430-435.
61. Zhu N, Gu L, Findley HW, Zhou M. 2005. Transcriptionalrepression of the eukaryotic initiation factor 4E gene by wild type p53. Biochem Biophys Res Commun 335: 1272-1279